Overview of the Phase 2 NEJM Trial Design and Participants Weight Loss Results at 48 Weeks: Key Percentage Findings Safety Profile and Side Effects Reported in the Trial How These Results Compare to Other Weight Loss Medicines What the Findings Mean for Future Treatment in the UK Frequently Asked Questions What Is Retatrutide and How Does It Work
These differences do not seem to be secondary to global changes in renal permeability, as urinary protein concentrations (normalized to urine creatinine levels) were unchanged (Figure 4D)
As with any GLP-1 medication, some patients experience mild digestive side effects such as nausea or mild discomfort, particularly when first starting treatment
weight loss drugs can harm a developing baby
Sang M, Xie C, Qiu S, et al
However, real-world patient reports and case discussions indicate that some individuals do experience this symptom, particularly in the first 24 weeks of starting treatment or during dose escalation phases
